HAEMONETICS CORP 8-K

What Happened

• On January 9, 2026 Haemonetics Corporation announced it acquired Vivasure Medical Limited, a Galway, Ireland–based company focused on next‑generation percutaneous vessel closure technology. The agreed purchase price was €100 million, which is approximately €52 million net after accounting for Haemonetics’ prior investments, loans to Vivasure and customary closing adjustments. Haemonetics also agreed to up to an additional €85 million in contingent consideration tied to sales growth and other milestones. The transaction was financed with available cash on hand.

Key Details

• Acquisition announced and filed in an 8‑K dated January 9, 2026.
• Upfront consideration: €100 million gross; ≈€52 million net after prior investments/loans and adjustments.
• Contingent consideration: up to €85 million based on sales growth and achievement of specified milestones (also subject to adjustment for prior investment/loan values).
• Target: Vivasure Medical Limited (Galway, Ireland) — developer of percutaneous vessel closure technology.
• Financing: transaction paid from Haemonetics’ available cash on hand.

Why It Matters

• The deal brings new percutaneous vessel closure technology into Haemonetics’ product portfolio and links part of the purchase price to future commercial performance through contingent payments.
• The upfront net cash outlay is relatively modest (≈€52M after adjustments) and was funded from cash on hand, which may affect Haemonetics’ cash resources but does not involve new debt financing per the filing.
• Investors should note the contingent consideration structure: up to €85M depends on future sales and milestone achievement, so the total cash impact will depend on Vivasure’s post‑acquisition commercial performance.